HEMOPHILIA A AND B
-
Dangerously high FIX levels reported in hemophilia B gene therapy
Montreal – June 29, 2020 – During the question-and-answer period of a session on gene therapy during the World Federation of Hemophilia’s virtual summit (June...
-
Home delivery for plasma protein products now in place
Montreal, May 21, 2020 – The Provinces and Territories announced this week a home delivery service for plasma protein products and their alternatives, including coagulation...
-
Biomarin’s gene therapy for hemophilia A to be called Roctavian
Montreal, May 14, 2020 – Biomarin announced on May 11 its gene therapy currently awaiting approval by the U.S. Food and Drug Administration will be...
-
Interview with Nurul Islam, president of the Hemophilia Society of Bangladesh
Interview with Nurul Islam, president of the Hemophilia Society of Bangladesh, about the role twinning played on their success in getting their government to fund...
-
Patient-reported outcomes via MyCBDR and PROBE: essential to patient advocacy
Montreal, April 17, 2020 – In recent years, the creation of electronic tools that allow people with hemophilia (PwH) to report their health outcomes to...